Results 281 to 290 of about 1,081,535 (384)

Hepatic resections for metastatic tumors [PDF]

, 1989
Iwatsuki, S, Starzl, TE
core  

CD44v, S1PR1, HER3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb

FEBS Open Bio, Volume 15, Issue 5, Page 867-884, May 2025.
Novel mAbs could detect cancer‐associated membrane proteins on various type of pancreatic ductal adenocarcinomas (PDAC) by flow cytometry with viable PDAC cells and by immunohistochemistry with PDAC tissues. Results of protein expression were substantiated by mRNA expression by The Cancer Genome Atlas.
Takashi Nakano, Kouki Okita, Shogo Okazaki, Soshi Yoshimoto, Sachiko Masuko, Hideki Yagi, Kazunori Kato, Yoshihisa Tomioka, Kenichi Imai, Yoichi Hamada, Kazue Masuko, Kayoko Shimada‐Takaura, Noriaki Nagai, Hideyuki Saya, Tomio Arai, Toshiyuki Ishiwata, Takashi Masuko   +16 more
wiley   +1 more source

Spontaneous branchioblastoma in a koi carp. [PDF]

J Vet Diagn Invest
Balducchi B, Henderson E.
europepmc   +1 more source

PO-081 Multiple primary malignant neoplasms of head and neck

, 2019
Z. Fèssi, N. Fourati, W. Mnejja, Wala Ben Kridis, Ilhem Charfeddine, Afef Khanfir, W. Siala, J. Daoud   +7 more
openalex   +1 more source

Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation

FEBS Open Bio, Volume 15, Issue 5, Page 836-855, May 2025.
Osimertinib reduces angiogenesis and PDL1 expression in in ovo tumors, transforming them into ‘cold tumors’ with lower immune activity. Anatomopathological and transcriptomic analyses highlight its therapeutic impact on tumor biology. This study underscores osimertinib's potential to reshape the tumor microenvironment and provides insights into its ...
David Barthélémy, Arnaud Vigneron, Xavier Rousset, Jérome Guitton, Emmanuel Grolleau, Margaux Raffin, Julie Balandier, Gaëlle Lescuyer, Mathilde Bardou, Florence Geiguer, Sébastien Couraud, Claire Bardel, Jean Viallet, Nazim Benzerdjeb, Léa Payen   +14 more
wiley   +1 more source

Metachronous gastro-oesophageal adenocarcinoma in a patient with colon adenocarcinoma. [PDF]

BMJ Case Rep
Meseeha M, Dudhat S, Sehrish L, Attia M.
europepmc   +1 more source

A potential tumor suppressor role of PLK2 in glioblastoma

FEBS Open Bio, Volume 15, Issue 5, Page 856-866, May 2025.
PLK2 was consistently downregulated in GBM tissues. Overexpression of PLK2 in GBM cell lines U87MG and U251 reduced their tumorigenic potential and enhanced cell cycle arrest and apoptosis. Suggesting that PLK2 overexpression could potentially be leveraged as a therapeutic strategy to inhibit tumor progression and enhance apoptosis, providing new ...
Xiangping Xia, Peirui Wang, Hua Xiao, Qishan Ran, Yan Li, Shengtao Yao   +5 more
wiley   +1 more source

A case report of situs inversus totalis undergoing multiple interventional strategies

Asian Journal of Surgery, 2023
Bingqing Ma, Biao Chen, Chengjun Cai, Jinxiang Zhang   +3 more
doaj  

Unraveling the genetic landscape of susceptibility to multiple primary cancers. [PDF]

HGG Adv
Middha P, Kachuri L, Nierenberg JL, Graff RE, Cavazos TB, Hoffmann TJ, Zhang J, Alexeeff S, Habel L, Corley DA, Van Den Eeden S, Kushi LH, Ziv E, Sakoda LC, Witte JS.   +14 more
europepmc   +1 more source

Identification of inhibitors of the Salmonella FraB deglycase, a drug target

FEBS Open Bio, Volume 15, Issue 5, Page 773-792, May 2025.
A high‐throughput screen was used to identify inhibitors of Salmonella FraB, a drug target. Characterization of top hits (identified after an additional counter screen) revealed that some triazolidines, thiadiazolidines, and triazolothiadiazoles are mixed‐type inhibitors of FraB.
Jamison D. Law, Yuan Gao, Sravya Kovvali, Pankajavalli Thirugnanasambantham, Vicki H. Wysocki, Brian M. M. Ahmer, Venkat Gopalan   +6 more
wiley   +1 more source